Menu

Markets

Research

News

Learn
Paper trading
AI Chat
Get the app WatchlistsPortfoliosAlerts
Sign in

Adaptimmune Therapeutics plc ADAPY

Set alert

Price alert · ADAPY

All alert types
0.02 USD 0.00 0.00%

As of Nov 2, 2:43 PM ET

0.0204 Day range 0.0278
0.001 52-week range 0.07
YTD
-21.15%
1 year
-59.00%
Open
0.0205
Prev close
0.0205
Mkt cap
5.43M
Vol
130.13K
Avg vol
187.90K
EPS
-0.67
P/E
0.00
More statistics
Low
0.0204
High
0.0278

3M chart

Chart tools
Interval
1m5m15m30m

Signals (25)
NameDateAgo
SMA: BearishOct 29, 20264 days ago
SMA: BullishOct 27, 20266 days ago
SMA: BearishOct 26, 20261 week ago
SMA: BearishOct 26, 20261 week ago
SMA: BullishOct 23, 20261 week ago
SMA: BullishOct 23, 20261 week ago
SMA: BearishOct 22, 20261 week ago
SMA: BearishOct 22, 20261 week ago
MACD: Sell SignalOct 22, 20261 week ago
MACD: Buy SignalOct 15, 20262 weeks ago
MACD: Sell SignalOct 13, 20262 weeks ago
SMA: BullishSep 30, 20261 month ago
SMA: BullishSep 25, 20261 month ago
SMA: BearishSep 22, 20261 month ago
SMA: BullishSep 21, 20261 month ago
MACD: Buy SignalSep 21, 20261 month ago
MACD: Sell SignalSep 17, 20261 month ago
MACD: Buy SignalSep 16, 20261 month ago
MACD: Sell SignalSep 10, 20261 month ago
MACD: Buy SignalSep 3, 20262 months ago

Newest 20 of 25.

Financial health

Altman Z-Score

-15.85 Distress zone

Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.

Piotroski F-Score

0 / 9 Weak

Nine pass/fail tests of profitability, leverage and efficiency.

Valuation

P/E -0.1×
FY 2016: -4.0×FY 2017: -8.6×FY 2018: -6.0×FY 2019: -0.9×FY 2020: -6.0×FY 2021: -3.7×FY 2022: -1.4×FY 2023: -1.4×FY 2024: -1.9×FY 2025: -0.1×
FY 2016 5y median -1.4× FY 2025
P/S 0.4×
FY 2016: 20.2×FY 2017: 15.5×FY 2018: 9.4×FY 2019: 112×FY 2020: 194×FY 2021: 95.0×FY 2022: 8.7×FY 2023: 2.6×FY 2024: 0.8×FY 2025: 0.4×
FY 2016 5y median 2.6× FY 2025
P/B 0.1×
FY 2016: 1.7×FY 2017: 2.9×FY 2018: 2.3×FY 2019: 1.0×FY 2020: 2.3×FY 2021: 2.8×FY 2022: 2.9×FY 2023: 4.0×FY 2024: 11.5×FY 2025: 0.1×
FY 2016 5y median 2.9× FY 2025
P/FCF 0.0×
FY 2016: -4.7×FY 2017: -7.4×FY 2018: -5.1×FY 2019: -1.1×FY 2020: -13.6×FY 2021: 300×FY 2022: -1.4×FY 2023: -1.1×FY 2024: -1.8×FY 2025: 0.0×
FY 2016 5y median -1.1× FY 2025
EV/EBITDA 0.2×
FY 2016: -1.8×FY 2017: -8.3×FY 2018: -8.4×FY 2019: -0.8×FY 2020: -5.8×FY 2021: -3.0×FY 2022: -1.0×FY 2023: -0.3×FY 2024: -2.3×FY 2025: 0.2×
FY 2016 5y median -1.0× FY 2025
EV/Sales -1.6×
FY 2016: 9.0×FY 2017: 16.6×FY 2018: 10.6×FY 2019: 90.0×FY 2020: 186×FY 2021: 74.8×FY 2022: 5.5×FY 2023: 0.7×FY 2024: 0.7×FY 2025: -1.6×
FY 2016 5y median 0.7× FY 2025
FCF Yield 0.0%
FY 2016: -21.3%FY 2017: -13.5%FY 2018: -19.5%FY 2019: -91.8%FY 2020: -7.4%FY 2021: 0.3%FY 2022: -72.9%FY 2023: -91.4%FY 2024: -55.9%FY 2025: 0.0%
FY 2016 5y median -55.9% FY 2025

Profitability

Gross Margin 100.0%
FY 2016: 100.0%FY 2017: 100.0%FY 2018: 100.0%FY 2019: -8589.9%FY 2020: -2213.5%FY 2021: -1706.6%FY 2022: -370.5%FY 2023: 83.6%FY 2024: 100.0%FY 2025: 100.0%
FY 2016 5y median 83.6% FY 2025
Operating Margin -1225.1%
FY 2016: -512.7%FY 2017: -213.2%FY 2018: -138.4%FY 2019: -12457.2%FY 2020: -3370.5%FY 2021: -2638.6%FY 2022: -604.0%FY 2023: -229.0%FY 2024: -38.6%FY 2025: -1225.1%
FY 2016 5y median -604.0% FY 2025
Net Margin 425.5%
FY 2016: -504.1%FY 2017: -185.4%FY 2018: -160.5%FY 2019: -12225.0%FY 2020: -3286.8%FY 2021: -2571.0%FY 2022: -609.5%FY 2023: -188.9%FY 2024: -39.8%FY 2025: 425.5%
FY 2016 5y median -188.9% FY 2025
ROE 78.8%
FY 2016: -43.1%FY 2017: -34.6%FY 2018: -38.7%FY 2019: -110.9%FY 2020: -38.1%FY 2021: -76.8%FY 2022: -202.1%FY 2023: -288.2%FY 2024: -597.6%FY 2025: 78.8%
FY 2016 5y median -202.1% FY 2025
ROIC -157.6%
FY 2016: -37.5%FY 2017: -39.0%FY 2018: -32.6%FY 2019: -93.4%FY 2020: -32.2%FY 2021: -39.6%FY 2022: -61.4%FY 2023: -64.1%FY 2024: -36.9%FY 2025: -157.6%
FY 2016 5y median -61.4% FY 2025
ROA 39.8%
FY 2016: -30.5%FY 2017: -24.9%FY 2018: -34.5%FY 2019: -75.6%FY 2020: -28.8%FY 2021: -33.7%FY 2022: -50.3%FY 2023: -40.3%FY 2024: -28.8%FY 2025: 39.8%
FY 2016 5y median -33.7% FY 2025

Growth (YoY)

Revenue -96.7%
FY 2016: 32.4%FY 2017: 166.5%FY 2018: 57.3%FY 2019: -98.1%FY 2020: 252.8%FY 2021: 55.4%FY 2022: 341.5%FY 2023: 122.0%FY 2024: 195.3%FY 2025: -96.7%
FY 2016 FY 2025
Operating Income -5.5%
FY 2016: -215.6%FY 2017: -10.8%FY 2018: -2.1%FY 2019: -69.7%FY 2020: 4.6%FY 2021: -21.6%FY 2022: -1.1%FY 2023: 15.8%FY 2024: 50.2%FY 2025: -5.5%
FY 2016 FY 2025
EPS (diluted) -6.8%
FY 2016: -70.0%FY 2017: 23.5%FY 2018: -23.1%FY 2019: -37.5%FY 2020: 31.8%FY 2021: -13.3%FY 2022: 0.0%FY 2023: 44.5%FY 2024: 50.4%FY 2025: -6.8%
FY 2016 FY 2025
Free Cash Flow 0.0%
FY 2016: -61.1%FY 2017: -30.1%FY 2018: -37.5%FY 2019: -5.9%FY 2020: 51.1%FY 2021: 103.4%FY 2022: -8904.4%FY 2023: 15.0%FY 2024: 47.9%FY 2025: 0.0%
FY 2016 FY 2025

Financial Health

Current Ratio 2.0×
FY 2016: 4.9×FY 2017: 3.1×FY 2018: 9.5×FY 2019: 3.5×FY 2020: 10.2×FY 2021: 6.6×FY 2022: 4.0×FY 2023: 2.9×FY 2024: 2.9×FY 2025: 2.0×
FY 2016 5y median 2.9× FY 2025
Quick Ratio 2.0×
FY 2016: 4.9×FY 2017: 3.0×FY 2018: 9.4×FY 2019: 3.5×FY 2020: 10.2×FY 2021: 6.6×FY 2022: 4.0×FY 2023: 2.9×FY 2024: 2.8×FY 2025: 2.0×
FY 2016 5y median 2.9× FY 2025
Debt / Equity 0.4×
FY 2016: 0.0×FY 2017: 0.6×FY 2018: 0.6×FY 2019: 0.2×FY 2020: 0.1×FY 2021: 0.1×FY 2022: 0.3×FY 2023: 0.6×FY 2024: 6.3×FY 2025: 0.4×
FY 2016 5y median 0.4× FY 2025
Net Debt / EBITDA 0.2×
FY 2016: 2.3×FY 2017: -0.5×FY 2018: -0.9×FY 2019: 0.2×FY 2020: 0.3×FY 2021: 0.8×FY 2022: 0.5×FY 2023: 0.9×FY 2024: 0.3×FY 2025: 0.2×
FY 2016 5y median 0.5× FY 2025
Interest Coverage 0.0×
FY 2016: 0.0×FY 2017: 0.0×FY 2018: 0.0×FY 2019: 0.0×FY 2020: 0.0×FY 2021: 0.0×FY 2022: 0.0×FY 2023: 0.0×FY 2024: -20.5×FY 2025: 0.0×
FY 2016 5y median 0.0× FY 2025

Dividends

Dividend Yield 0.0%
FY 2016: 0.0%FY 2017: 0.0%FY 2018: 0.0%FY 2019: 0.0%FY 2020: 0.0%FY 2021: 0.0%FY 2022: 0.0%FY 2023: 0.0%FY 2024: 0.0%FY 2025: 0.0%
FY 2016 5y median 0.0% FY 2025
Payout Ratio 0.0%
FY 2016: 0.0%FY 2017: 0.0%FY 2018: 0.0%FY 2019: 0.0%FY 2020: 0.0%FY 2021: 0.0%FY 2022: 0.0%FY 2023: 0.0%FY 2024: 0.0%FY 2025: 0.0%
FY 2016 5y median 0.0% FY 2025

Annual · latest fiscal year ends 2025-12-31